105 – Season 7 Recap & Future Directions (S7E15)

It feels like every day there's a new headline
about some amazing new drug or therapy. Oh, absolutely.
And it's not just about the drugs themselves,
you know, the molecules they're discovering.
Right. It's the really incredible ways that they're
figuring out how to actually deliver those therapies,
get them into the body where they need to be.
It's mind blowing the pace of it all. Yeah. And
I imagine for a lot of people out there trying
to keep up with the science behind it. Oh, for
sure. it can feel like drinking from a fire hose.
Absolutely. Well, that's where we come in. That's
right. Think of this as your cheat sheet, your
rapid download of the really essential stuff.
Exactly. And today, we're not dissecting the
latest blockbuster drug. Right. We're diving
into the really ingenious science of how those
drugs are formulated and delivered, how they
actually get to where they need to go in the
body. So it's not just about what the drug is,
it's about how we get it there. That's it. And
today we're doing something a little bit special.
A little different. We're taking a trip back
to Season 7. Yeah, a little retrospective. Specifically
focusing on the advancements we explored in formulation
and drug delivery. Precisely a look back to see
where we're headed. Think of it as the essential
takeaways from Season 7 all wrapped up in one
neat little package. But it's not just a walk
down memory lane, is it? No. It's about understanding
how those scientific leaps we discussed in getting
drugs into the system are now influencing the
regulations that govern them, what happens once
they're approved and on the market, and ultimately
the future of how we design medicines. Making
those connections, right? Exactly. And seeing
the big picture. So we're going to be extracting
the most significant insights from the season,
revealing how these intricate details, these
seemingly complex technical aspects have very
real, tangible, real world consequences. It's
about those aha moments. Exactly. Where things
suddenly click into place. Precisely the understanding
that might not have been apparent in those individual
discussions. Right. And season seven really was.
packed full of exciting advancements, wasn't
it? It really was. We explored everything from
the incredibly small world of nanoparticles to
really sophisticated strategies for getting drugs
past tough barriers like the skin. Absolutely.
It was a really comprehensive season. OK, let's
jump in. Let's do it. When we think about the
big breakthroughs in formulation from season
seven, where should we start? Well a really fundamental
area we covered and one that's absolutely crucial
in the early stages of drug development Something
we actually touched on way back in season three
is the significance of a drugs solid state properties,
right and That might sound kind of basic, but
it's actually incredibly important, isn't it?
It really is. You might recall us discussing
how a drug substance can exist in different physical
forms, like various crystal structures or different
sized particles. It's like how graphite and diamonds
are both made of carbon, right? Exactly. But
their structures give them completely different
properties. Absolutely. And the same principle
applies to drug molecules. These different solid
forms can have a profound effect on a drug's
stability. So, how long it remains effective,
its solubility, how well it dissolves in the
body, and ultimately its bioavailability, the
extent to which its absorbed and is available
to have an effect. Right. It's not enough for
a drug to just exist. It has to exist in the
right form to actually work in the body. Precisely.
And as we discussed in season three, even seemingly
minor variations in crystal structure or particle
size can present major challenges in formulating
a drug and can even impact how easily it can
be manufactured consistently. So it's like a
recipe. Yes. You know, if you change the ingredients
even slightly, even a little bit, it can completely
change the end result. Exactly. You can end up
with a cake instead of a cookie or a souffle
instead of a pancake. It's all about understanding
and controlling those fundamental properties.
So controlling a drug's crystal structure is
like controlling the fundamental building blocks
of how it behaves in the body. Exactly. It impacts
everything from how long it sits on the shelf
to how effectively it treats a disease. So really
nailing down these solid state properties right
from the beginning is absolutely essential. It's
fundamental. What other formulation innovations
from season seven really stand out? Well, we
dedicated quite a bit of time to liposomes. Liposomes,
those tiny little bubbles of fat. Well, they're
microscopic spheres constructed from fat -like
molecules. OK. And what's particularly interesting
about them is their potential to greatly enhance
the oral bioavailability of drugs, whether those
drugs are oily or water -soluble. Right. So whether
the drug itself likes to dissolve in oil or in
water. Exactly. Liposomes can help it get absorbed
better when taken by mouth. Precisely. And they're
biodegradable and biocompatible, which is important.
Right. break down naturally in the body and don't
cause harm. Exactly. So how do they work? Yeah.
How do they achieve that enhanced absorption?
Well, their structure is really key. They have
this double layer of lipids that allows them
to interact very favorably with the mucosal lining
of the gut. So they basically blend in. In a
way, yes. They can also form mixed micelles with
bile salts, which are naturally present in the
digestive system. And bile salts help to break
down Fats. Right, exactly. And that aids in dissolving
those more challenging lipophilic drugs, the
ones that like to dissolve in oil. Ah, so it's
like a team effort. Percyclic. The liposomes
and the bile salts work together. To help the
drug get absorbed. And there's even research
suggesting that liposomes could be useful for
targeting the lymphatic system. There is, which
is very promising. So potentially delivering
drugs directly to the immune system. Precisely.
That's pretty amazing. It is very exciting. But
we also discussed some hurdles with getting liposomes
to work effectively when taken orally, didn't
we? We did. There were some challenges right
there. Yes, their stability in the gastrointestinal
tract is a primary concern. Right, it's a pretty
harsh environment down there. It is very acidic
and full of enzymes that can break things down.
So how do you protect these delicate little liposomes?
Well, researchers are developing some really
ingenious solutions. One strategy is to incorporate
stabilizing lipids directly into the liposome
structure. Ah, so reinforcing them from within.
Precisely. Another approach is to coat them with
protective polymers. Like giving them a suit
of armor. Exactly. And then there are even more
complex systems like double liposomes or proliposomes
and bilisomes. Those sound pretty high -tech.
They are. They involve multiple layers and compartments
that can help to further enhance stability and
control the release of the drug. So it's like
giving these tiny drug carriers a protective
suit for their journey through the digestive
system. A very good analogy. And in Season 7
we also explored formulations designed specifically
for inhalation. Yes, we did specifically dry
- powder inhalers or DPIs and pressurized metered
dose inhalers or PMDIs. Right, those are the
devices that people use to deliver medication
directly to their lungs. Exactly, for conditions
like asthma or COPD. And these delivery systems
are surprisingly complex, aren't they? They are
much more so than you might think. You know,
I always just imagined it was like spraying a
fine mist. Well, it is, but achieving the precise
particle size required for the drug to effectively
reach deep into the lungs? That's a real challenge.
Right, because if the particles are too big...
They'll get trapped in the upper airways. And
if they're too small, they might just be exhaled.
So it's a real Goldilocks situation. It is. You
need the particles to be just the right size.
And then there's ensuring consistent dosing with
each inhalation. Right, because you don't want
people getting too much or too little medication
with each puff. Exactly. And then there are factors
like powder flow in DPIs or the behavior of propellants
in PMDIs that all have to be carefully controlled.
So a lot of engineering goes into these devices.
That's a great deal. Fascinating. And then we
shifted gears a bit in season seven and talked
about the challenge of getting drugs through
the skin transdermal drug delivery. Yes, that's
an area with a lot of potential, but also some
significant obstacles. I imagine so. We discussed
how excipients, the inactive ingredients in a
drug formulation, can play a crucial role by
inducing localized changes in the outermost layer
of the skin, the stratum corneum. That's the
tough outer layer that acts as a barrier. Exactly.
And the objective is to identify chemical permeation
enhancers, or CPEs. Right. CPEs? Yes. These are
excipients that can temporarily loosen that barrier.
So it's like finding a key to unlock the skin.
In a way, yes. And the ideal CPE needs to have
a very specific set of characteristics. So it's
not just any old chemical. No. It needs to be
pharmacologically inert, meaning it doesn't have
its own medicinal effect. Right. So it's not
adding any extra drug to the mix. Exactly. It
should have a predictable and reversible action.
So you know how it's going to behave. Precisely.
And that the effect is temporary. And it needs
to be safe. Absolutely. It can't cause any irritation
or toxic effects. So finding these ideal CPEs
is kind of like a holy grail. In a way, yes.
The search is ongoing and it's a significant
area of research. Which is why the range of drugs
currently suitable for transdermal delivery is
still somewhat limited. Exactly. We're still
looking for those perfect keys to unlock the
skin's potential. Well, hopefully we'll get there.
And we also briefly touched upon the use of colloids
in drug delivery. We did. Colloids are essentially
very fine particles suspended within a liquid.
Okay, so like a really fine mist. In a way, yes,
and they offer another versatile strategy for
drug delivery. And we're talking about things
like nanoparticles here? Yes, nanoparticles are
one example. They can be specifically engineered
to possess properties that are ideal for targeted
drug delivery or for enhancing the solubility
of poorly soluble drugs. So it's all about manipulating
these tiny particles to behave in very specific
ways. Precisely. Fascinating. So clearly a lot
of innovation happening on the formulation front.
Absolutely, a very dynamic field. Now let's pivot
a bit and talk about advancements in how we actually
deliver these formulated drugs. What were some
of the key takeaways there from season seven?
Well, a major area of ongoing development is
modified release formulations for oral administration.
Modified release. So that means controlling when
and how the drug is released. Exactly. Instead
of the drug being released all at once, leading
to a spike and then a drop in concentration,
these formulations are designed to release the
drug more gradually over a sustained period.
Right. So it's like a slow and steady release.
Precisely. Rather than a burst all at once. Exactly.
And this can have a number of benefits. Like
what? Well, for one, it can result in more consistent
drug levels in the bloodstream. Right, so instead
of having these big peaks and valleys... Exactly.
You get a more stable level. Precisely. And that
can translate to less frequent dosing. So instead
of having to take a pill three times a day...
You might only need to take it once a day. Which
could lead to better patient adherence. Exactly.
People are more likely to stick to their medication
regimen if it's simpler and more convenient.
Right, because no one wants to be constantly
reminded to take their pills. Precisely. and
modified release can also help to reduce side
effects. Well, by avoiding those high peaks in
drug concentration, you can minimize the risk
of adverse effects that might be associated with
those high levels. So it's a win -win. It can
be. And all these formulation advancements we've
been discussing, they're ultimately aimed at
achieving very specific pharmacokinetic profiles
for the drug in the body. Pharmacokinetics, that's
the study of how the body processes a drug. Exactly.
It's all about understanding how the drug is
absorbed, distributed, metabolized, and eliminated.
Right. ADME. Precisely. And this connects directly
back to some fundamental pharmacokinetic principles
we explored in earlier seasons. For instance,
in season five, we discussed how impaired kidney
function can significantly impact how drugs are
eliminated from the body. Right. If a patient's
kidneys aren't working efficiently. The drug
might remain in their system for an extended
period. Which could be dangerous. It could potentially
lead to toxicities. So that directly influences
how we need to formulate and dose drugs for those
patients. Absolutely. And similarly, in season
two, we took a deep dive into drug metabolism.
Drug metabolism. That's the process by which
the body breaks down and eliminates drugs. Precisely.
It primarily occurs in the liver. And often involves
those cytochrome P450 enzymes. Yes, like CYP3A4
and CYP3A5. Right. CYP enzymes. They're kind
of like the body's drug detoxification system.
A good way to think about it. And understanding
which specific enzymes a drug interacts with
is vital, because variations in these enzymes
between individuals can significantly alter how
quickly they process medications. So some people
might break down a drug very quickly, while others
might break it down much more slowly, which could
affect how well the drug works. Absolutely. So
we need to consider all these factors when we're
designing formulations. It's really complex,
isn't it? It is, but it's fascinating. OK, so
we've seen these really exciting innovations
in how formulate and deliver drugs. How do these
advancements then intersect with the regulatory
world and what happens after a drug receives
approval and is on the market? That's where the
practical implications really come into focus.
Right, because it's not enough to just have a
great idea. You have to be able to actually get
it approved and out to patients. Exactly. And
these complex formulations and delivery technologies
necessitate a very thorough consideration by
regulatory agencies. So they really scrutinize
these new approaches? Absolutely. They need to
ensure that the products are safe, effective,
and manufactured to the highest standards. A
concept that was a recurring theme in season
seven and is absolutely central to this discussion
is quality by design or QBD. Yes, QBD is all
about building quality into the product from
the outset based on robust scientific evidence
and a comprehensive understanding of potential
risks. So it's a more proactive approach to drug
development. Exactly. Rather than just testing
for quality at the end of the process, QBD emphasizes
understanding and controlling all the factors
that can influence quality throughout the entire
life cycle of the product. And we discussed how
a thorough understanding of polymorphism those
different solid forms of a drug we talked about
earlier, is absolutely critical for conducting
effective QBD -based risk assessments. Precisely
because if an unexpected crystal form emerges
during manufacturing or storage, it could completely
alter the drug's properties and its performance
in patients. Right, so you need to know what
you're dealing with. Exactly. And QBD is about
anticipating those potential risks and putting
controls in place to mitigate them. It's like
a more holistic approach to drug development.
Exactly. It's about understanding the entire
system and how all the pieces fit together. And
then there's dissolution testing. which we discussed
in season five when we explored the development
of solid oral dosage forms. Dissolution testing
might seem like a relatively straightforward
test, simply observing how quickly a tablet or
capsule dissolves. Right. But it's actually a
vital tool for ensuring consistency between different
batches of the same drug product. So it's like
a quality control check. Precisely. And it can
also serve as an early indicator of any changes
in the formulation that might affect how the
drug behaves once it's in the body. So if a tablet
suddenly starts dissolving much faster or slower
than it should. That could be a sign that something
has changed in the formulation. And that could
affect how the drug is absorbed. Exactly. And
if you can establish a reliable in vitro in vivo
correlation or IVIVC, That's a highly valuable
outcome, isn't it? Yeah, it is indeed highly
desirable. Because it means that the results
of an in -lab dissolution test can reliably predict
how the drug will be absorbed and behave in the
living organism. Exactly. It allows the in -vitro
test to serve as a surrogate for in -vivo behavior.
Which can potentially reduce the reliance on
extensive bioequivalence studies in humans. Precisely.
And speaking of bioequivalence, that's another
really critical area. Bioequivalence. That's
the concept of demonstrating that two different
formulations of the same drug deliver the drug
to the body in a comparable way. Exactly. And
as we discussed in Season 7 and as outlined in
regulations like CFR Title 21 Part 320, demonstrating
comparable bioavailability between different
formulations of the same drug or even between
different production batches is absolutely essential.
So if a pharmaceutical company makes a change
to the formulation of an existing drug, They'll
likely need to conduct studies to show that the
new version delivers the drug to the body in
a way that's comparable to the original. Right.
So it's not enough to just change the recipe.
Exactly. You need to demonstrate that the change
doesn't affect how the drug is absorbed and behaves
in the body. And then we have stability studies.
Yes, stability studies are crucial for determining
the shelf life of a drug product and for ensuring
that it maintains its required quality attributes
throughout its intended life cycle. Right, because
no one wants a medication that loses its potency
or degrades before it can even be used by the
patient. Precisely. And regulatory submissions
invariably require comprehensive stability protocols
that detail the specific storage conditions,
the time points at which the product will be
tested, and the acceptance criteria it must meet
at each of those points. So these studies are
really important for ensuring the quality and
safety of drug products. Absolutely. And finally,
let's consider the post -marketing phase. Post
-marketing. So that's after the drug has already
been approved and is available to patients. Exactly.
Even after a drug has received regulatory approval,
the choices made in formulation and delivery
continue to have important implications. So the
story doesn't end once the drug is on the market.
Not at all. Ensuring consistent product quality
and performance in real world use, particularly
for more complex formulations, can present ongoing
challenges. So it's an ongoing process of monitoring
and evaluation. Precisely. We discussed the importance
of having robust systems for handling any complaints
about the drug product that might arise and the
detailed record keeping requirements that are
mandated by regulations like CFR Title 21 Part
211. So it's about being prepared to address
any issues that might come up. Exactly. And having
systems in place to track and investigate those
issues. It sounds like these exciting advancements
in formulation and delivery while offering tremendous
benefits. also introduce significant layers of
complexity to both the regulatory approval process
and the ongoing monitoring of drug products after
they reach the market. They do indeed, but it's
a necessary complexity. Right, because ultimately
it's all about ensuring the safety and efficacy
of these new medicines. Exactly. And the insights
we gain from these advancements, the challenges
we encounter and ultimately overcome are precisely
what's fueling the next wave of innovation in
how we design pharmaceutical products. So how
are these lessons learned from the past? shaping
the future of drug development. We're seeing
a very clear trend towards the development of
more sophisticated drug delivery systems. More
sophisticated in what way? Well, the overarching
goal is to improve the efficacy of treatments
to reduce unwanted side effects and ultimately
to enhance patient compliance. So it's about
making treatments more effective, safer, and
easier to use. Exactly. We're talking about things
like longer acting injectable formulations that
reduce the frequency of injections or even smart
pills that can release their payload at a specific
location within the digestive tract. So it's
about targeting the drug more precisely. Exactly,
getting it to where it needs to be in the body
with minimal side effects. And these advancements
are closely intertwined with the fundamental
principles of pharmaceutical process development,
an area we explored in depth in season four and
revisited in season seven. Absolutely. A deep
understanding of the critical quality attributes
or CQAs of a drug product, those specific properties
that are essential for its safety and its ability
to produce the desired therapeutic effect, and
the critical process parameters or CPPs, the
variables within the manufacturing process that
can influence those CQAs is absolutely paramount.
And this is where sophisticated tools like design
of experiments or DOE come into play. Precisely,
DOE allows us to methodically study how different
process parameters interact with each other and
to identify the optimal operating conditions
that will consistently produce a high -quality
product. It's like fine -tuning the manufacturing
process. Exactly. And we're also observing a
growing interest and adoption of continuous manufacturing
processes. Continuous manufacturing. So that's
different from the traditional batch processing.
Exactly. Rather than producing drugs in discrete
batches, continuous manufacturing involves an
integrated process that runs uninterrupted. Which
can potentially improve both efficiency and the
consistency of quality control. Precisely. It's
a more streamlined and efficient way to manufacture
medicines. That sounds like a real step forward.
It is. And finally, the increasing and evolving
role of modeling and simulation, something we
touched upon in both season four and season seven,
is becoming increasingly crucial. Modeling and
simulation. So that's using computer models to
predict how a drug will behave. Exactly. These
powerful computational tools allow us to predict
how a drug product will perform in the body and
to optimize both the formulation itself and the
delivery system before we even proceed to large
-scale manufacturing or extensive clinical trials.
So it's a way to front load the development process.
Precisely. We can identify and address potential
problems early on before they become costly or
time -consuming to fix. That sounds like a very
smart approach. It is, and it has the potential
to significantly streamline drug development.
Which ultimately benefits everyone. Absolutely.
This has been a really insightful recap of Season
7. It's been a pleasure. It's fascinating to
see how all these seemingly disparate pieces
of information connect and point towards the
future of pharmaceutical development. It's all
interconnected. So looking ahead, what can our
listeners anticipate in upcoming deep dives?
We'll be continuing to explore critical areas
that really build upon the groundwork we've covered
in season seven. We plan to delve into the crucial
world of compliance, likely with a focus on good
manufacturing practices or GMPs. GMPs. Yeah.
Those are the regulations that govern the manufacturing
of drug product. Exactly. And we'll be exploring
what it takes to consistently ensure the quality
and safety of drug products throughout their
entire life cycle, from raw materials to the
finished product reaching the patient. So a really
deep dive into the manufacturing process. Precisely.
And we also intend to examine the concept of
real -world effectiveness, looking at how drugs
actually perform once they're being used by patients
in everyday settings. Right. Because clinical
trials can only tell us so much. Exactly. It's
important to see how drugs actually work in the
real world. Precisely. And this involves the
important fields of pharmacovigilance and the
analysis of post -market data. So keeping track
of how drugs are performing once they're out
in the market. Exactly. And of course, we'll
continue to keep a close watch on evolving trends
within the pharmaceutical industry, including
the exciting possibilities of personalized medicine
and the emergence of innovative new therapeutic
modalities. Personalized medicine, so tailoring
treatments to individual patients. Precisely.
And new therapeutic modalities, things like gene
therapy and cell therapy. That's some really
cutting edge stuff. It is a very exciting time
to be in this field. It sounds like we'll continue
to follow the entire journey of a medicine. From
that initial spark of scientific discovery all
the way through to its impact on the lives of
patients. Absolutely. It's a constantly evolving
and learning process. It is. Well, this has been
a truly illuminating look back at the key advancements
of season seven and a fascinating glimpse into
what lies ahead. So to leave you with a final
thought, the remarkable progress we're seeing
in drug delivery is unlocking incredibly exciting
possibilities for how we treat diseases. But
the true impact of these cutting -edge technologies
will depend on our collective ability to consistently
translate them into safe and effective treatments
that make a real difference in the lives of patients.
What do you see as the biggest remaining hurdles
we need to overcome to fully realize this potential?
It's something to consider until our next deep
dive. Thanks for being with us. It's been a pleasure,
as always. Until next time. See you then.